Dogwood Therapeutics, Inc. (DWTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.74

From 52W high−79.27%

Volume109229.00

Market cap$55.75M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.74

From 52W high

−79.27%

Volume

109229.00

Market cap

$55.75M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

P/E (TTM)

—

RSI (14)

36.1

MomentumView details →

1D Return

−4.65%

YTD Return

−59.38%

SummaryUpdated Jun 1, 2026

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is a development-stage biotechnology company founded in 2012 and headquartered in Alpharetta, Georgia. The company was formerly known as Virios Therapeutics, Inc. before changing its name to Dogwood Therapeutics in October 2024. As a clinical-stage biotech firm, Dogwood focuses on developing novel antiviral therapies designed to treat diseases associated with viral-triggered abnormal immune responses, representing a specialized approach within the broader biotechnology industry.

Ask drillr about Dogwood Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−52.72%

ROA (TTM)

−44.77%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+51.33%

FCF YoY

+4.08%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+65.50%

EBITDA YoY

−20.91%

MomentumView details →

1D Return

−4.65%

YTD Return

−59.38%

1Y Return

−66.27%

RSI (14)

36.1

vs 50D SMA

−11.23%

vs 200D SMA

−32.86%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.89x

Quick Ratio

3.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

−142.86%

Beats (12Q)

5/12

Next Q EPS Est

−$0.16

Avg Surprise (4Q)

−183.91%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−36.04M

Op. CF (TTM)

−15.11M

Next earningsNov 5, 2026 →

Latest newsMore news →

Dogwood Therapeutics completed patient enrollment in its ongoing Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, enrolling 239 patients.6d ago

Dogwood Therapeutics announced its financial results for the second quarter of 2026.38d ago

Similar companies

Kezar Life Sciences, Inc.KZR ImageneBio IncIMA NOMAD Power Solutions, Inc.NMAD PDS Biotechnology CorporationPDSB Heron Therapeutics, Inc.HRTX Coeptis Therapeutics, Inc.COEP Find similar companies →

Latest newsMore news →

Dogwood Therapeutics completed patient enrollment in its ongoing Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, enrolling 239 patients.6d ago Dogwood Therapeutics announced its financial results for the second quarter of 2026.38d ago